Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Income from Continuing Operations (2016 - 2025)

Lisata Therapeutics' Income from Continuing Operations history spans 13 years, with the latest figure at 2954000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 35.92% year-over-year to 2954000.0; the TTM value through Dec 2025 reached 16586000.0, up 17.01%, while the annual FY2025 figure was 16586000.0, 17.01% up from the prior year.
  • Income from Continuing Operations reached 2954000.0 in Q4 2025 per LSTA's latest filing, up from 4249000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2954000.0 in Q4 2025 to a low of 6187000.0 in Q1 2023.
  • Average Income from Continuing Operations over 3 years is 4784250.0, with a median of 4827000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: dropped 25.25% in 2024, then surged 35.92% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 5365000.0 in 2023, then grew by 14.07% to 4610000.0 in 2024, then soared by 35.92% to 2954000.0 in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Income from Continuing Operations are 2954000.0 (Q4 2025), 4249000.0 (Q3 2025), and 4659000.0 (Q2 2025).